Search Result

Results for "

Phlotoxin-1 (PhlTx1) 是一种含有 34 个氨基酸和 3-二硫键的多肽。Phlotoxin-1 可以从<i>Phlogiellus</i>属蜘蛛中分离出来。Phlotoxin-1 是一种通过抑制 <b>NaV1.7</b> 通道而发挥作用的抗伤害试剂。

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Calcium Channel (1) Cytochrome P450 (1) iGluR (1) Isotope-Labeled Compounds (1) Potassium Channel (4) Small Interfering RNA (siRNA) (1) Sodium Channel (95)
By Research Areas:	Cancer (1) Cardiovascular Disease (5) Infection (2) Inflammation/Immunology (8) Metabolic Disease (1) Neurological Disease (82)

Inhibitors & Agonists

Peptides

Natural
Products

Isotope-Labeled Compounds

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-13985

Nav1.7 inhibitor	Sodium Channel	Neurological Disease
Nav1.7 inhibitor (compound II), a sulfonamide, is a potent *Nav1.7* inhibitor. Nav1.7 inhibitor has the potential for a wide range of disorders, particularly pain ^[1].

HY-126429

Nav1.1 activator 1	Sodium Channel	Neurological Disease
Nav1.1 activator 1 (compound 4), a highly potent *Na_v1.1* activator with BBB penetration, increases decay time constant τ of Na_v1.1 currents at 0.03 μM along with significant selectivity against Na_v1.2, Na_v1.5, and Na_v1.6 ^[1].

HY-P5160

Phlotoxin-1 PhlTx1	Sodium Channel	Inflammation/Immunology
Phlotoxin-1 (PhlTx1) is a 34-amino acid and 3-disulfide bridge peptide. Phlotoxin-1 can be isolated from Phlogiellus genus spider. Phlotoxin-1 is an antinociceptive agent by inhibiting *NaV1.7* channel ^[1] .

HY-RS09046

NAV1 Human Pre-designed siRNA Set A	Small Interfering RNA (siRNA)	Others
NAV1 Human Pre-designed siRNA Set A contains three designed siRNAs for NAV1 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

NAV1 Human Pre-designed siRNA Set A NAV1 Human Pre-designed siRNA Set A

HY-160588

Nav1.8-IN-7	Sodium Channel Potassium Channel	Neurological Disease
Nav1.8-IN-7 (Example 116) is a selective *Nav1.8* inhibitor. Nav1.8-IN-7 shows an inhibition of >50% with 100 nM for Nav1.8. Nav1.8-IN-7 inhibits hERG with an IC₅₀ of 15.6 μM. Nav1.8-IN-7 has the potential for pain research ^[1].

HY-160589

Nav1.8-IN-8	Sodium Channel	Neurological Disease
Nav1.8-IN-8 (Compound A11) is a *Nav1.8* channel inhibitor. Nav1.8-IN-8 may prevent associated diseases mediated by sodium ion channels (NaV) .

HY-160591

Nav1.8-IN-10	Sodium Channel	Neurological Disease
Nav1.8-IN-10 (Compound 6) is a *Nav1.8* channel inhibitor. When the concentration is 4 nM, the percentage blocking rate of Nav1.8 channel is 79.4%. Nav1.8-IN-10 can be used in the study of pain disorders ^[1].

HY-160593

Nav1.8-IN-12

Sodium Channel Neurological Disease

Nav1.8-IN-12 (Compound 23 R) is a Nav1.8 channel inhibitor. Nav1.8-IN-12 can be used in the study of pain-related diseases ^[1].

Nav1.8-IN-12	Sodium Channel	Neurological Disease
Nav1.8-IN-12 (Compound 23 R) is a *Nav1.8* channel inhibitor. Nav1.8-IN-12 can be used in the study of pain-related diseases ^[1].

HY-162246

Nav1.8-IN-5	Sodium Channel	Cardiovascular Disease Neurological Disease
Nav1.8-IN-5 (Example 1) is a voltage-gated sodium channel *Nav1.8* inhibitor. Nav1.8-IN-5 can be used for Nav1.8-mediated diseases, such as pain and pain-related disorders, as well as cardiovascular diseases (such as atrial fibrillation) research ^[1].

HY-160592

Nav1.8-IN-11	Sodium Channel	Neurological Disease
Nav1.8-IN-11 (Example 1) is a *Nav1.8* channel inhibitor with a IC₅₀ value of 0.1 nM. Nav1.8-IN-11 can be used in the study of pain disorders ^[1].

HY-155635

Nav1.8-IN-4

Sodium Channel Infection

Nav1.8-IN-4 (compound 9a) is a Nav1.8 channel inhibitor (IC₅₀=0.014 μM). Nav1.8-IN-4 can be used for research on pain-related diseases ^[1].

Nav1.8-IN-4	Sodium Channel	Infection
Nav1.8-IN-4 (compound 9a) is a *Nav1.8* channel inhibitor (IC₅₀=0.014 μM). Nav1.8-IN-4 can be used for research on pain-related diseases ^[1].

HY-141547

Nav1.7-IN-8	Sodium Channel Cytochrome P450	Inflammation/Immunology
Nav1.7-IN-8 is a potent blockage of *NaV1.7* with high selectivity for the inhibition of *NaV1.7* over the subtypes hNaV1.1 and hNaV1.5. Nav1.7-IN-8 inhibits CYP2C9 and CYP3A4 with an IC₅₀ of 0.17 μM and 0.077 μM, respectively. Nav1.7-IN-8 displays significant analgesic effects in rodent models of acute and inflammatory pain ^[1].

HY-116194

NaV1.7 blocker-801

Sodium Channel Neurological Disease

NaV1.7 blocker-801 is a NaV1.7 channel blocker that can be used in the study of neurological diseases ^[1].

NaV1.7 blocker-801	Sodium Channel	Neurological Disease
NaV1.7 blocker-801 is a NaV1.7 channel blocker that can be used in the study of neurological diseases ^[1].

HY-143481

Nav1.8-IN-2	Sodium Channel	Neurological Disease
Nav1.8-IN-2 (compound 35A) is a potent *Na_v1.8* inhibitor with an IC₅₀ value of 0.4 nM. Nav1.8-IN-2 can be used for researching pain disorders, cough disorders, and acute and chronic itch disorders ^[1].

HY-102998

Nav1.7-IN-6

Sodium Channel Neurological Disease

Nav1.7-IN-6 (example 346) is a Nav1.7 selective inhibitor, which is extracted from patent WO2015078374A1 ^[1].

Nav1.7-IN-6	Sodium Channel	Neurological Disease
Nav1.7-IN-6 (example 346) is a *Nav1.7* selective inhibitor, which is extracted from patent WO2015078374A1 ^[1].

HY-161272

Nav1.8-IN-6	Sodium Channel	Neurological Disease
Nav1.8-IN-6 (Compound 2j) is a novel pyridinone amide Nav1.8 channel inhibitor. The IC₅₀ values in the resting state and semi-activated state are 513.33 and 471.81 nM, respectively. Nav1.8-IN-6 has analgesic activity ^[1].

HY-101789

Nav1.7-IN-3	Sodium Channel	Neurological Disease
Nav1.7-IN-3 is a selective, orally bioavailable voltage-gated sodium channel Nav1.7 inhibitor with an IC₅₀ of 8 nM. Pain relief. Limited CNS penetration ^[1].

HY-132133

Nav1.8-IN-1	Sodium Channel	Neurological Disease Inflammation/Immunology
Nav1.8-IN-1 (Compound 31) is a potent inhibitor of Na(v)1.8 sodium channel. Nav1.8-IN-1 has the potential for the research of inflammatory and neuropathic pain ^[1].

HY-155058

Nav1.3 channel inhibitor 1	Sodium Channel	Neurological Disease
Nav1.3 channel inhibitor 1 (compound 15b) is a state-dependent voltage-gated sodium channel Na_v1.3 inhibitor (IC₅₀=20 nM). Nav1.3 channel inhibitor 1 can penetrate the blood-brain barrier and can be used in the research of nervous system diseases ^[1].

HY-19366

Nav1.7-IN-2

Nav1.7-IN-2 is an inhibitor of voltage-gated sodium channels (Nav), in particular Nav 1.7, with IC50 of 80 nM.

Nav1.7-IN-2
Nav1.7-IN-2 is an inhibitor of voltage-gated sodium channels (Nav), in particular Nav 1.7, with IC50 of 80 nM.

HY-162347

Nav1.7-IN-13	Sodium Channel	Neurological Disease
Nav1.7-IN-13 (compound 3g) is a sodium channel inhibitor that significantly inhibits Veratridine (HY-N6691)-induced neuronal activity. Nav1.7-IN-13 inhibits total Na+ current in DRG neurons in a concentration-dependent manner; slows down the activation of Navs. Nav1.7-IN-13 significantly alleviated mechanical pain behavior in a rat model of nerve injury (SNI) and had analgesic activity ^[1].

HY-152166

NaV1.2/1.6 channel blocker-1	Sodium Channel	Neurological Disease
NaV1.2/1.6 channel blocker-1 is a potent NaV1.2/1.6 channel blocker, with IC₅₀s of 9.8 and 24.4 μM for *rNaV1.6* and *hNaV1.2, respectively. NaV1.2/1.6 channel blocker*-1 can be used for the research of generalized epilepsy ^[1].

HY-160663

Nav1.7 blocker 1	Sodium Channel	Neurological Disease Inflammation/Immunology
Nav1.7 blocker 1 (example 41) is a Na ⁺ channel (Na_v) blocker with an IC₅₀ value of 0.037 μM. Nav1.7 blocker 1 can be used for the study of pain, including neuropathic pain, postoperative pain, inflammatory pain, and so on ^[1].

HY-119934

NaV1.7 inhibitor-1	Sodium Channel	Neurological Disease
NaV1.7 inhibitor-1 is an efficacious voltage-gated sodium channel (NaV) 1.7 inhibitor with an IC₅₀ of 0.6 nM for hNaV1.7, exhibits 80-fold selectivity versus hNaV1.5 ^[1].

HY-P5795

GsAF-I	Sodium Channel Potassium Channel	Neurological Disease
GsAF-I is a potent *Na_v* and *hERG1* channels blocker with IC₅₀s of 0.36, 0.6, 1.28, 0.33, 1.2, 0.04 and 4.8 μM against Na_v1.1, Na_v1.2, Na_v1.3, Na_v1.4, Na_v1.6, Na_v1.7 and hERG1, respectively ^[1].

HY-133910

Lu AE98134	Sodium Channel	Neurological Disease
Lu AE98134, an activator of voltage-gated sodium channels, acts as a partly selective Na_v1.1 channels positive modulator. Lu AE98134 also increases the activity of Na_v1.2 and Na_v1.5 channels but not of Na_v1.4, Na_v1.6 and Na_v1.7 channels. Lu AE98134 can be used to analyze pathophysiological functions of the Na_v1.1 channel in various central nervous system diseases, including cognitive restoring in schizophrenia, et al ^[1].

HY-16787

ICA-121431 2 Publications Verification	Sodium Channel	Cardiovascular Disease
ICA-121431 is a nanomolar potent and broad-spectrum voltage-gated sodium channel (Na_v) blocker, shows equipotent selectivity for human Na_v1.1 and Na_v1.3 subtypes with IC₅₀ values of 13 nM and 23 nM, respectively. ICA-121431 shows less potent inhibition of Na_v1.2 (IC₅₀=240 nM) and 1,000 fold selectivity against Na_v1.4, Na_v1.6, and the TTX-resistant human Na_v1.5 and Na_v1.8 channels (IC₅₀s >10 µM).

HY-P5164

GrTx1	Sodium Channel	Neurological Disease
GrTx1 is a peptide toxin originally isolated from the venom of the spider Grammostola rosea. GrTx1 blocks sodium channel， with IC₅₀s of 0.63 µM, 0.23 µM, 0.77 µM, 1.29 µM, 0.63 µM and 0.37 µM for Nav1.1, Nav1.2, Nav1.3, Nav1.4, Nav1.6 and Nav1.7, repectively ^[2].GrTx1 can be used for neurological disease research ^[1].

HY-125079

DSP-2230

Sodium Channel Cardiovascular Disease Neurological Disease

DSP-2230 is a selective Nav1.7/Nav1.8 blocker ^[1] .

DSP-2230	Sodium Channel	Cardiovascular Disease Neurological Disease
DSP-2230 is a selective *Nav1.7/Nav1.8* blocker ^[1] .

HY-P1220

Huwentoxin-IV	Sodium Channel	Neurological Disease
Huwentoxin-IV is a potent and selective sodium channel blocker, inhibits neuronal *Nav1.7, Nav1.2, Nav1.3* and *Nav1.4* with IC₅₀s of 26, 150, 338 and 400 nM, respectively. Huwentoxin-IV preferentially blocks peripheral nerve subtype Nav1.7 by binding neurotoxin receptor site 4. Huwentoxin-IV has analgesic effects on animal models of inflammatory and neuropathic pain ^[1] .

HY-P1220A

Huwentoxin-IV TFA	Sodium Channel	Neurological Disease
Huwentoxin-IV TFA is a potent and selective sodium channel blocker, inhibits neuronal *Nav1.7, Nav1.2, Nav1.3* and *Nav1.4* with IC₅₀s of 26, 150, 338 and 400 nM, respectively. Huwentoxin-IV TFA preferentially blocks peripheral nerve subtype Nav1.7 by binding neurotoxin receptor site 4. Huwentoxin-IV TFA has analgesic effects on animal models of inflammatory and neuropathic pain ^[1] .

HY-P1218A

Phrixotoxin 3 TFA	Sodium Channel	Neurological Disease
Phrixotoxin 3 TFA is a potent blocker of voltage-gated sodium channels, with IC₅₀s of 0.6, 42, 72, 288, 610 nM for *NaV1.2, NaV1.3, NaV1.4, NaV1.1* and *NaV1.5, respectively. Phrixotoxin 3 TFA modulates voltage-gated sodium channels with properties similar to those of typical gating-modifier toxins*, both by causing a depolarizing shift in gating kinetics and by blocking the inward component of the sodium current ^[1].

HY-P1218

Phrixotoxin 3	Sodium Channel	Neurological Disease
Phrixotoxin 3 is a potent blocker of voltage-gated sodium channels, with IC₅₀s of 0.6, 42, 72, 288, 610 nM for *NaV1.2, NaV1.3, NaV1.4, NaV1.1* and *NaV1.5, respectively. Phrixotoxin 3 modulates voltage-gated sodium channels with properties similar to those of typical gating-modifier toxins*, both by causing a depolarizing shift in gating kinetics and by blocking the inward component of the sodium current ^[1].

HY-126985

4,9-Anhydrotetrodotoxin Anhydroepitetrodotoxin	Sodium Channel	Neurological Disease
4,9-Anhydrotetrodotoxin is a selective voltage-gated sodium channel (VGSC) inhibitor that blocks Nav1.1 and Nav1.6 in human brain and induces a hyperpolarizing shift in the voltage dependence of inactivated Nav1.6 ^[1].

HY-P5786

Heteropodatoxin-1	Potassium Channel Sodium Channel	Neurological Disease
Heteropodatoxin-1 (HpTx1), a spider peptide toxin, is a Kv4.2 current inhibitor. Heteropodatoxin-1 also inhibits *Nav1.7* and activates *Nav1.9* but does not affect Nav1.8 ^[1].

HY-103623

PF-05241328

Sodium Channel Neurological Disease

PF-05241328 is a potent and selective inhibitor of human Nav1.7 voltage-dependent sodium channels (Nav1.7), with an IC₅₀ of 31 nM.

PF-05241328	Sodium Channel	Neurological Disease
PF-05241328 is a potent and selective inhibitor of human Nav1.7 voltage-dependent sodium channels *(Nav1.7), with an IC₅₀* of 31 nM.

HY-157802

LTGO-33	Sodium Channel	Neurological Disease
LTGO-33 is a potent and selective voltage-gated sodium channel *NaV1.8* inhibitor. LTGO-33 inhibits NaV1.8 in the nM potency range and exhibits over 600-fold selectivity against human NaV1.1-NaV1.7 and NaV1.9. LTGO-33 exhibits state-independent inhibition with similar potencies on channels in the closed and inactivated conformations. LTGO-33 inhibits native TTX-R NaV1.8 currents in non-human primate and human DRG neurons, where it reduces action potential firing. LTGO-33 can be used for pain disorders research ^[1].

HY-P5811

Ceratotoxin-1 CcoTx1; β-TRTX-cm1a	Sodium Channel	Neurological Disease
Ceratotoxin-1 (CcoTx1), a peptide toxin, is an voltage-gated sodium channel subtypes inhibitor. Ceratotoxin-1 inhibits *Nav1.1/β1, Nav1.2/β1, Nav1.4/β1, and Nav1.5/β1* with IC₅₀ of 523 nM, 3 nM, 888 nM, and 323 nM, respectively. Ceratotoxin-1 also inhibits *Nav1.8/β1* ^[1].

HY-101383

PF-01247324 1 Publications Verification	Sodium Channel	Neurological Disease
PF-01247324 is a selective and orally bioavailable *Na_v1.8* channel blocker with an IC₅₀ of 196 nM for recombinant human Na_v1.8 channel.

HY-N1847

3'-Methoxydaidzein	Sodium Channel	Neurological Disease
3'-Methoxydaidzein is a isoflavone and a Sodium Channel inhibitor. 3'-Methoxydaidzein inhibits subtypes NaV1.7, NaV1.8 and NaV1.3 with IC₅₀ of 181 nM, 397 nM, and 505 nM, respectively. 3'-Methoxydaidzein exerts analgesic activity by inhibiting voltage-gated sodium channels ^[1].

HY-P5801

Phlo1a μ-TrTx-Phlo1a	Sodium Channel	Neurological Disease
Phlo1a (μ-TrTx-Phlo1a) is a peptide toxin contains 35-amino acid residues. Phlo1b is a selective *Nav1.7* inhibitor. Phlo1a has a weak inhibitory effect on Nav1.2 and Nav1.5 ^[1].

HY-100727

AM-2099

Sodium Channel Neurological Disease

AM-2099 is a potent and selective inhibitor of voltage-gated sodium channel Nav1.7 with an IC₅₀ of 0.16 μM for human Nav1.7.

AM-2099	Sodium Channel	Neurological Disease
AM-2099 is a potent and selective inhibitor of voltage-gated sodium channel *Nav1.7* with an IC₅₀ of 0.16 μM for human Nav1.7.

HY-P5800

Phlo1b μ-TrTx-Phlo1b	Sodium Channel	Neurological Disease
Phlo1b (μ-TrTx-Phlo1b) is a peptide toxin contains 35-amino acid residues. Phlo1b is a selective *Nav1.7* inhibitor. Phlo1b has a weak inhibitory effect on Nav1.2 and Nav1.5 ^[1].

HY-12811

PF-04856264	Sodium Channel	Neurological Disease
PF-04856264 is a potent and selective *Nav1.7* inhibitor, with IC₅₀s of 28, 131, 19, and 42 nM for human, mouse, cynomolgus monkey and dog Nav1.7, respectively. PF-04856264 has low potency against the rat Nav1.7 channel. PF-04856264 shows analgesic effect ^[1] .

HY-P5793

GTx1-15	Sodium Channel Calcium Channel	Neurological Disease
GTx1-15 is an inhibitor cystine knot (ICK) peptide that inhibits the voltage-dependent calcium channel Cav3.1 and the voltage-dependent sodium channels Nav1.3 and *Nav1.7* ^[1].

HY-P5865

Tap1a Theraphotoxin-Tap1a; TRTX-Tap1a; µ/ω-TRTX-Tap1a	Sodium Channel	Neurological Disease
Tap1a (Theraphotoxin-Tap1a) is a spider venom peptide that inhibits sodium channels with IC₅₀s of 80 nM and 301 nM against Na_v1.7 and Na_v1.1, respectively. Tap1a shows analgesic effects ^[1].

HY-157786

XPC-5462	Sodium Channel	Neurological Disease
XPC-5462 is a *NaV1.6* and *NaV1.2* inhibitor with the IC₅₀s of 10.9 nM and 10.3 nM, respectively. XPC-5462 suppresses epileptiform activity in an ex vivo brain slice seizure model ^[1].

HY-B0262

Methocarbamol	Sodium Channel	Neurological Disease
Methocarbamol is an orally active central muscle relaxant and blocks muscular Nav1.4 channel. Methocarbamol reversibly affects voltage dependence of inactivation of Nav1.4 channel. Methocarbamol has the potential for muscle spasms and pain syndromes research ^[1] .

HY-149944

Analgesic agent-2	Sodium Channel	Inflammation/Immunology
Analgesic agent-2 is a selective and orally active NaV1.8 Channel inhibitor, with an IC₅₀ of 50.18 nM in HEK293 cells stably expressing human NaV1.8 channel. Analgesic agent-2 has analgesic activity ^[1].

HY-P5810

Ceratotoxin-2 CcoTx2; β-TRTX-cm1b	Sodium Channel	Neurological Disease
Ceratotoxin-2 (CcoTx2) is a voltage-gated sodium channel blocker with IC₅₀s of 8 nM and 88 nM against Na_v1.2/β₁ and Na_v1.3/β₁, respectively ^[1].

Cat. No.	Product Name	Target	Research Area

HY-P5160

Phlotoxin-1 PhlTx1	Sodium Channel	Inflammation/Immunology
Phlotoxin-1 (PhlTx1) is a 34-amino acid and 3-disulfide bridge peptide. Phlotoxin-1 can be isolated from Phlogiellus genus spider. Phlotoxin-1 is an antinociceptive agent by inhibiting *NaV1.7* channel ^[1] .

HY-P5795

GsAF-I	Sodium Channel Potassium Channel	Neurological Disease
GsAF-I is a potent *Na_v* and *hERG1* channels blocker with IC₅₀s of 0.36, 0.6, 1.28, 0.33, 1.2, 0.04 and 4.8 μM against Na_v1.1, Na_v1.2, Na_v1.3, Na_v1.4, Na_v1.6, Na_v1.7 and hERG1, respectively ^[1].

HY-P5164

GrTx1	Sodium Channel	Neurological Disease
GrTx1 is a peptide toxin originally isolated from the venom of the spider Grammostola rosea. GrTx1 blocks sodium channel， with IC₅₀s of 0.63 µM, 0.23 µM, 0.77 µM, 1.29 µM, 0.63 µM and 0.37 µM for Nav1.1, Nav1.2, Nav1.3, Nav1.4, Nav1.6 and Nav1.7, repectively ^[2].GrTx1 can be used for neurological disease research ^[1].

HY-P1220

Huwentoxin-IV	Sodium Channel	Neurological Disease
Huwentoxin-IV is a potent and selective sodium channel blocker, inhibits neuronal *Nav1.7, Nav1.2, Nav1.3* and *Nav1.4* with IC₅₀s of 26, 150, 338 and 400 nM, respectively. Huwentoxin-IV preferentially blocks peripheral nerve subtype Nav1.7 by binding neurotoxin receptor site 4. Huwentoxin-IV has analgesic effects on animal models of inflammatory and neuropathic pain ^[1] .

HY-P1220A

Huwentoxin-IV TFA	Sodium Channel	Neurological Disease
Huwentoxin-IV TFA is a potent and selective sodium channel blocker, inhibits neuronal *Nav1.7, Nav1.2, Nav1.3* and *Nav1.4* with IC₅₀s of 26, 150, 338 and 400 nM, respectively. Huwentoxin-IV TFA preferentially blocks peripheral nerve subtype Nav1.7 by binding neurotoxin receptor site 4. Huwentoxin-IV TFA has analgesic effects on animal models of inflammatory and neuropathic pain ^[1] .

HY-P1218A

Phrixotoxin 3 TFA	Sodium Channel	Neurological Disease
Phrixotoxin 3 TFA is a potent blocker of voltage-gated sodium channels, with IC₅₀s of 0.6, 42, 72, 288, 610 nM for *NaV1.2, NaV1.3, NaV1.4, NaV1.1* and *NaV1.5, respectively. Phrixotoxin 3 TFA modulates voltage-gated sodium channels with properties similar to those of typical gating-modifier toxins*, both by causing a depolarizing shift in gating kinetics and by blocking the inward component of the sodium current ^[1].

HY-P1218

Phrixotoxin 3	Sodium Channel	Neurological Disease
Phrixotoxin 3 is a potent blocker of voltage-gated sodium channels, with IC₅₀s of 0.6, 42, 72, 288, 610 nM for *NaV1.2, NaV1.3, NaV1.4, NaV1.1* and *NaV1.5, respectively. Phrixotoxin 3 modulates voltage-gated sodium channels with properties similar to those of typical gating-modifier toxins*, both by causing a depolarizing shift in gating kinetics and by blocking the inward component of the sodium current ^[1].

HY-P5786

Heteropodatoxin-1	Potassium Channel Sodium Channel	Neurological Disease
Heteropodatoxin-1 (HpTx1), a spider peptide toxin, is a Kv4.2 current inhibitor. Heteropodatoxin-1 also inhibits *Nav1.7* and activates *Nav1.9* but does not affect Nav1.8 ^[1].

HY-P5811

Ceratotoxin-1 CcoTx1; β-TRTX-cm1a	Sodium Channel	Neurological Disease
Ceratotoxin-1 (CcoTx1), a peptide toxin, is an voltage-gated sodium channel subtypes inhibitor. Ceratotoxin-1 inhibits *Nav1.1/β1, Nav1.2/β1, Nav1.4/β1, and Nav1.5/β1* with IC₅₀ of 523 nM, 3 nM, 888 nM, and 323 nM, respectively. Ceratotoxin-1 also inhibits *Nav1.8/β1* ^[1].

HY-P5801

Phlo1a μ-TrTx-Phlo1a	Sodium Channel	Neurological Disease
Phlo1a (μ-TrTx-Phlo1a) is a peptide toxin contains 35-amino acid residues. Phlo1b is a selective *Nav1.7* inhibitor. Phlo1a has a weak inhibitory effect on Nav1.2 and Nav1.5 ^[1].

HY-P5800

Phlo1b μ-TrTx-Phlo1b	Sodium Channel	Neurological Disease
Phlo1b (μ-TrTx-Phlo1b) is a peptide toxin contains 35-amino acid residues. Phlo1b is a selective *Nav1.7* inhibitor. Phlo1b has a weak inhibitory effect on Nav1.2 and Nav1.5 ^[1].

HY-P5793

GTx1-15	Sodium Channel Calcium Channel	Neurological Disease
GTx1-15 is an inhibitor cystine knot (ICK) peptide that inhibits the voltage-dependent calcium channel Cav3.1 and the voltage-dependent sodium channels Nav1.3 and *Nav1.7* ^[1].

HY-P5865

Tap1a Theraphotoxin-Tap1a; TRTX-Tap1a; µ/ω-TRTX-Tap1a	Sodium Channel	Neurological Disease
Tap1a (Theraphotoxin-Tap1a) is a spider venom peptide that inhibits sodium channels with IC₅₀s of 80 nM and 301 nM against Na_v1.7 and Na_v1.1, respectively. Tap1a shows analgesic effects ^[1].

HY-P5810

Ceratotoxin-2 CcoTx2; β-TRTX-cm1b	Sodium Channel	Neurological Disease
Ceratotoxin-2 (CcoTx2) is a voltage-gated sodium channel blocker with IC₅₀s of 8 nM and 88 nM against Na_v1.2/β₁ and Na_v1.3/β₁, respectively ^[1].

HY-P1681

GpTx-1

Sodium Channel Neurological Disease

GpTx-1 is a potent and selective Na_V1.7 antagonist with an IC₅₀ of 10 nM ^[1].
HY-P5336

μ-Conotoxin Sx IIIA

Sodium Channel Others

μ-Conotoxin Sx IIIA is a biological active peptide. (NaV1.4 Channels Blocker)

HY-P5781

δ-Theraphotoxin-Hm1b	Sodium Channel	Neurological Disease
δ-Theraphotoxin-Hm1b is a 42-amino acid peptide isolated from Togo starburst tarantula (Heteroscodra maculata) venom. δ-Theraphotoxin-Hm1b selectively inhibits inactivation of *NaV1.1* but have no effect on NaV1.7 ^[1].

HY-P5177

GsAF-II	Sodium Channel Potassium Channel	Neurological Disease
GsAF-II is a peptide toxin that blocks hERG1 subtype potassium channels in a voltage-dependent manner. GsAF-II blocks Nav1.x subtype sodium channels ^[1].

HY-P5861

µ-Conotoxin BuIIIC

Mu-Conotoxin BuIIIC
Sodium Channel Neurological Disease

μ-Conotoxin BuIIIC (Mu-Conotoxin BuIIIC) is a potent Na_v1.4 inhibitor ^[1].

HY-P1221

ProTx II	Sodium Channel	Neurological Disease
ProTx II is a selective blocker of Nav1.7 sodium channels with an IC₅₀ of 0.3 nM, and is at least 100-fold selective for Nav1.7 over other sodium channel subtypes. ProTx-II inhibits sodium channels by decreasing channel conductance and shifting activation to more positive potentials and blocks action potential propagation in nociceptors ^[1] .

HY-P1221A

ProTx II TFA	Sodium Channel	Neurological Disease
ProTx II TFA is a selective blocker of Nav1.7 sodium channels with an IC₅₀ of 0.3 nM, and is at least 100-fold selective for Nav1.7 over other sodium channel subtypes. ProTx-II inhibits sodium channels by decreasing channel conductance and shifting activation to more positive potentials and blocks action potential propagation in nociceptors ^[1] .

HY-P5808A

Iota-conotoxin RXIA TFA

Sodium Channel Neurological Disease

Iota-conotoxin RXIA (TFA) is an agonist of voltage-gated sodium ion channels NaV1.2, 1.6 and 1.7 ^[1].
HY-P5809

Pe1b

μ-TrTx-Pe1b
Sodium Channel Neurological Disease

Pe1b (μ-TrTx-Pe1b) is a selective Na_v1.7 inhibitor with an IC₅₀ of 167 nM ^[1].

HY-P5183

Hm1a	Sodium Channel	Neurological Disease
Hm1a is a disulfide-rich spider-venom peptide, and a *NaV1.1* activator. Hm1a restores the function of inhibitory interneurons in Dravet syndrome (DS) mouse model ^[1].

HY-P1443

OD1	Sodium Channel	Cancer
OD1 is a scorpion α-toxin that can be isolated from the venom of the Iranian yellow scorpion (Odonthobuthus doriae. OD1 is a modulator of mammalian *Nav1.7* (EC₅₀: 4.5 nM) ^[1] .

HY-P1952A

µ-Conotoxin-CnIIIC acetate	Sodium Channel	Neurological Disease
µ-Conotoxin-CnIIIC acetate, a 22-residue conopeptide, is a potent antagonist of the voltage-gated NaV1.4 sodium channel with an IC₅₀ of 1.3 nM acting at the neuromuscular junction. µ-Conotoxin-CnIIIC acetate has myorelaxant and analgesic effects ^[1].

HY-P5783

δ-Buthitoxin-Hj2a	Sodium Channel	Neurological Disease
δ-Buthitoxin-Hj2a, a scorpion-venom peptide, is a potent *NaV1.1* agonist with an EC₅₀ of 32 nM. δ-Buthitoxin-Hj2a can be used for the Dravet syndrome (DS) research ^[1].

HY-P5784

δ-Buthitoxin-Hj1a	Sodium Channel	Neurological Disease
δ-Buthitoxin-Hj1a, a scorpion-venom peptide, is a potent *NaV1.1* agonist with an EC₅₀ of 17nM. δ-Buthitoxin-Hj1a can be used for the Dravet syndrome (DS) research ^[1].

HY-P5808

Iota-conotoxin RXIA	Peptides	Neurological Disease
lota-conotoxin RXIA is an agonist of voltage-gated sodium channels (Na_v1.2, 1.6, 1.7). Iota-conotoxin RXIA can induce repetitive action potential and seizure in motor axons of frogs after intracranial injection in mice ^[1].

Cat. No.	Product Name	Category	Target	Chemical Structure

HY-N1847

3'-Methoxydaidzein	Structural Classification Flavonoids Leguminosae Source classification Maackia amurensis Rupr. et Maxim. Plants Isoflavones	Sodium Channel
3'-Methoxydaidzein is a isoflavone and a Sodium Channel inhibitor. 3'-Methoxydaidzein inhibits subtypes NaV1.7, NaV1.8 and NaV1.3 with IC₅₀ of 181 nM, 397 nM, and 505 nM, respectively. 3'-Methoxydaidzein exerts analgesic activity by inhibiting voltage-gated sodium channels ^[1].

HY-155236

Ancistrotecine B	Structural Classification Alkaloids Piperidine Alkaloids Source classification Ancistrocladus tectorius (Lour.) Merr. Plants Ancistrocladaceae	Sodium Channel
Ancistrotecine B (Compound 2) is a *Nav1.7* channel inhibitor (IC₅₀: 0.73 μM). Ancistrotecine B relieves inflammatory pain in mice ^[1].

Cat. No.	Product Name	Chemical Structure

HY-B0262S1

Methocarbamol-d3
Methocarbamol-d₃ is the deuterium labeled Methocarbamol. Methocarbamol is an orally active central muscle relaxant and blocks muscular Nav1.4 channel. Methocarbamol reversibly affects voltage dependence of inactivation of Nav1.4 channel. Methocarbamol has the potential for muscle spasms and pain syndromes research[1][2][3].

HY-B0262S2

Methocarbamol-13C,d3
Methocarbamol- ¹³C,d₃ is the ¹³C- and deuterium labeled Methocarbamol. Methocarbamol is an orally active central muscle relaxant and blocks muscular Nav1.4 channel. Methocarbamol reversibly affects voltage dependence of inactivation of Nav1.4 channel. Methocarbamol has the potential for muscle spasms and pain syndromes research[1][2][3].

HY-B0262S

Methocarbamol D5

Methocarbamol-d₅ is deuterium labeled Methocarbamol. Methocarbamol is an orally active central muscle relaxant and blocks muscular Nav1.4 channel[1].

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks